|
|
| |
These programs were planned and conducted by the corporate community in conjunction with the American Diabetes Association's 66th Annual Scientific Sessions. They provide attendees with additional educational/informational opportunities. Program content and product information are the sole responsibility of the organizers. |
 |
Practical Approaches for the Effecive Use of Insuling Analogs: Integrating Evidence into Practice
Supported by an unrestricted grant from Novo Nordisk, Inc.
The epidemic of diabetes is raging out of control. More than 20 million Americans have diabetes; an additional 41 million have prediabetes. Recent statistics show that 2 out of 3 patients are not achieving glycemic targets, which puts them at risk for severely debilitating or fatal complications. There is compelling evidence that intensive treatment of diabetes decreases the chronic complications of the disease. There appears to be no glycemic threshold for reduction of complications; thus, the goal of therapy is the lowest A1C level possible without unacceptable adverse effects. Early initiation of therapy, including insulin analogs when appropriate, with timely and persistent titration to achieve glycemic targets should be the standard of care for all patients. All insulin treatment strategies need to be individualized to patient needs. This symposium will follow a case through different scenarios of patient profiles. Initial treatment strategies for each particular patient will be discussed, including the rationale for implementing various insulin strategies. Issues presented (including compliance and adherence) will force the faculty to develop an appropriate “best practice” therapy. Three principal insulin-initiation strategies (basal once a day, prandial [bolus] as needed, and premixed twice a day) will be reviewed. |
 |
Managing
Cardiometabolic Risk: Will New Approaches Improve Success?
Supported by an unrestricted educational grant provided by the Sanofi-Aventis Group
Common cardiovascular and metabolic (cardiometabolic) risk factors in high-risk patients include dyslipidemia, insulin resistance, hypertension, and abdominal adiposity. Abdominal adiposity is an important underlying risk factor for clinical atherosclerotic disease and, along with other cardiometabolic risk factors, requires early identification and management. Overstimulation of the endocannabinoid system, a newly identified physiologic system involved in lipid and glucose metabolism, is associated with the development of various cardiometabolic risk factors. Cannabinoid (CB) receptors, specifically CB1 receptors, found in the brain and in various peripheral organs, play a pivotal role in regulating energy balance and body weight. Blockade of CB1 receptors has been shown to improve various cardiometabolic risk factors in obese or overweight patients, even in patients with pre-existing diabetes and dyslipidemia. This symposium examines how to improve outcomes in high-risk patients through targeted risk-reduction strategies aimed at each patient’s individual cardiometabolic risk-factor profile. Current and new risk-reduction approached are discussed. |
 |
Hearings and Confirmations: Insulin Strategies for Mitigating Inpatient Hyperglycemia
Supported by an unrestricted grant from Novo Nordisk, Inc.
In 2002, hospital discharges associated with diabetes amounted to 4.9 million, a number that has more than doubled over the last 20 years. For every 2 patients in the hospital with known diabetes, there may be an additional one with newly observed hyperglycemia. The cost of inpatient diabetes care is estimated at $40 billion— the single largest component of its direct medical costs. Compelling evidence continues to accumulate to suggest that poorly controlled glucose levels are associated with increased morbidity and mortality in hospitalized patients.
Until recently, glycemic control in hospitalized patients has not been a major therapeutic focus. In the last 3 years, however, substantial data as well as 2 consensus conferences have established a strong rationale for addressing hyperglycemia in hospitalized patients. |
 |
Debating the Management of Diabetes Type 2 With Emerging Therapies
This program is presented in conjunction with the Council for the Advancement of Diabetes Research and Education (CADRE) and is supported by an unrestricted educational grant from Pfizer Inc.
The benefits of insulin in delaying or even preventing diabetes progression are becoming increasingly recognized, and forthcoming non-invasive formulations of insulin will make it a more acceptable option for diabetes management early in the disease. The incretin therapies may also have the potential of improving pancreatic function and delaying diabetes progression. This satellite symposium, which will be moderated in a “town hall” format, will provide a platform for investigators of non-invasive insulin formulations and incretin therapies to discuss the merits of these emerging approaches to the management of diabetes. |
|
